

# Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy

Giacomo Grasselli, MD; Massimiliano Greco, MD; Alberto Zanella, MD; Giovanni Albano, MD; Massimo Antonelli, MD; Giacomo Bellani, MD, PhD; Ezio Bonanomi, MD; Luca Cabrini, MD; Eleonora Carlesso, MS; Gianpaolo Castelli, MD; Sergio Cattaneo, MD; Danilo Cereda, MD; Sergio Colombo, MD; Antonio Coluccello, MD; Giuseppe Crescini, MD; Andrea Forastieri Molinari, MD; Giuseppe Foti, MD; Roberto Fumagalli, MD; Giorgio Antonio Iotti, MD; Thomas Langer, MD; Nicola Latronico, MD; Ferdinando Luca Lorini, MD; Francesco Mojoli, MD; Giuseppe Natalini, MD; Carla Maria Pessina, MD; Vito Marco Ranieri, MD; Roberto Rech, MD; Luigia Scudeller, MD; Antonio Rosano, MD; Enrico Storti, MD; B. Taylor Thompson, MD; Marcello Tirani, MD; Pier Giorgio Villani, MD; Antonio Pesenti, MD; Maurizio Cecconi, MD; for the COVID-19 Lombardy ICU Network

[+ Supplemental content](#)

**IMPORTANCE** Many patients with coronavirus disease 2019 (COVID-19) are critically ill and require care in the intensive care unit (ICU).

**OBJECTIVE** To evaluate the independent risk factors associated with mortality of patients with COVID-19 requiring treatment in ICUs in the Lombardy region of Italy.

**DESIGN, SETTING, AND PARTICIPANTS** This retrospective, observational cohort study included 3988 consecutive critically ill patients with laboratory-confirmed COVID-19 referred for ICU admission to the coordinating center (Fondazione IRCCS [Istituto di Ricovero e Cura a Carattere Scientifico] Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy) of the COVID-19 Lombardy ICU Network from February 20 to April 22, 2020. Infection with severe acute respiratory syndrome coronavirus 2 was confirmed by real-time reverse transcriptase-polymerase chain reaction assay of nasopharyngeal swabs. Follow-up was completed on May 30, 2020.

**EXPOSURES** Baseline characteristics, comorbidities, long-term medications, and ventilatory support at ICU admission.

**MAIN OUTCOMES AND MEASURES** Time to death in days from ICU admission to hospital discharge. The independent risk factors associated with mortality were evaluated with a multivariable Cox proportional hazards regression.

**RESULTS** Of the 3988 patients included in this cohort study, the median age was 63 (interquartile range [IQR] 56-69) years; 3188 (79.9%; 95% CI, 78.7%-81.1%) were men, and 1998 of 3300 (60.5%; 95% CI, 58.9%-62.2%) had at least 1 comorbidity. At ICU admission, 2929 patients (87.3%; 95% CI, 86.1%-88.4%) required invasive mechanical ventilation (IMV). The median follow-up was 44 (95% CI, 40-47; IQR, 11-69; range, 0-100) days; median time from symptoms onset to ICU admission was 10 (95% CI, 9-10; IQR, 6-14) days; median length of ICU stay was 12 (95% CI, 12-13; IQR, 6-21) days; and median length of IMV was 10 (95% CI, 10-11; IQR, 6-17) days. Cumulative observation time was 164 305 patient-days. Hospital and ICU mortality rates were 12 (95% CI, 11-12) and 27 (95% CI, 26-29) per 1000 patients-days, respectively. In the subgroup of the first 1715 patients, as of May 30, 2020, 865 (50.4%) had been discharged from the ICU, 836 (48.7%) had died in the ICU, and 14 (0.8%) were still in the ICU; overall, 915 patients (53.4%) died in the hospital. Independent risk factors associated with mortality included older age (hazard ratio [HR], 1.75; 95% CI, 1.60-1.92), male sex (HR, 1.57; 95% CI, 1.31-1.88), high fraction of inspired oxygen (FiO<sub>2</sub>) (HR, 1.14; 95% CI, 1.10-1.19), high positive end-expiratory pressure (HR, 1.04; 95% CI, 1.01-1.06) or low PaO<sub>2</sub>:FiO<sub>2</sub> ratio (HR, 0.80; 95% CI, 0.74-0.87) on ICU admission, and history of chronic obstructive pulmonary disease (HR, 1.68; 95% CI, 1.28-2.19), hypercholesterolemia (HR, 1.25; 95% CI, 1.02-1.52), and type 2 diabetes (HR, 1.18; 95% CI, 1.01-1.39). No medication was independently associated with mortality (angiotensin-converting enzyme inhibitors HR, 1.17; 95% CI, 0.97-1.42; angiotensin receptor blockers HR, 1.05; 95% CI, 0.85-1.29).

**CONCLUSIONS AND RELEVANCE** In this retrospective cohort study of critically ill patients admitted to ICUs in Lombardy, Italy, with laboratory-confirmed COVID-19, most patients required IMV. The mortality rate and absolute mortality were high.

JAMA Intern Med. doi:10.1001/jamainternmed.2020.3539  
Published online July 15, 2020.

**Author Affiliations:** Author affiliations are listed at the end of this article.

**Group Information:** Members of the COVID-19 Lombardy ICU Network are listed at the end of the article.

**Corresponding Author:** Alberto Zanella, MD, Dipartimento di Anestesia-Rianimazione e Emergenza Urgenza, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca' Granda Ospedale Maggiore Policlinico, Via Della Commenda 16, 20122 Milano, Italy (alberto.zanella@unimi.it).

As of June 16, 2020, 8 251 224 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and 445 188 coronavirus disease 2019 (COVID-19)-related deaths had been reported worldwide.<sup>1</sup> Among active cases, 1.6% (54 593 of 3 503 249) are in severe or critical condition.

Lombardy, a region of Northern Italy, was the epicenter of the first COVID-19 outbreak in a western country.<sup>2</sup> On April 22, 3940 of 69 092 laboratory-confirmed cases (5.7%) required admission to one of the intensive care units (ICUs) of the COVID-19 Lombardy ICU Network.<sup>3</sup> Knowledge of baseline patient characteristics and risk factors associated with ICU and hospital mortality is still limited. Male sex, hypertension, cardiovascular disorders, and type 2 diabetes are the most prevalent comorbidities, and they are associated with a high case fatality rate.<sup>4-11</sup> The prevalence of chronic obstructive pulmonary disease is typically less than 10%.<sup>4,6-8,10-12</sup> It has been hypothesized that the use of drugs acting on the renin-angiotensin system may be associated with the course of the disease, because SARS-CoV-2 enters the host cells by binding to the angiotensin-converting enzyme 2 (ACE2).<sup>6,13-17</sup>

Acute respiratory distress syndrome has been diagnosed in 40% to 96%<sup>6-8,12,18</sup> of the patients admitted to the ICU. Need for invasive mechanical ventilation (IMV) varied widely between the different case series but is invariably associated with high mortality,<sup>4-6,8,10,18,19</sup> with ICU mortality ranging from 16% to 78%.<sup>7-9,11,12,18-20</sup> A prior study from the COVID-19 Lombardy ICU Network<sup>5</sup> reported an ICU mortality of 25.6% (15% aged 14-63 years; 36% aged 64-91 years); however, 58.2% of patients were still in the ICU at the end of follow-up.

We herein report ICU and hospital outcomes of the first 3988 patients critically ill with COVID-19 referred to the Coordinating Center (Fondazione IRCCS [Istituto di Ricovero e Cura a Carattere Scientifico] Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy) of the COVID-19 Lombardy ICU Network.<sup>2,5</sup> Some data from the first 1591 patients have been previously reported.<sup>5</sup> We describe the baseline characteristics of the patients, comorbidities, concomitant treatments at the time of hospital admission, mode and setting of ventilatory support, and the association of these characteristics with time to death.

## Methods

### Patients and Data Collection

The institutional ethics board of Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, approved this study and waived the need for informed consent from individual patients owing to the retrospective nature of the study. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.

This retrospective, observational study enrolled all consecutive patients with confirmed SARS-CoV-2 infection admitted to one of the Network ICUs from February 20 to April 22, 2020. To the best of our knowledge, all the critically ill patients requiring ICU admission in Lombardy have been referred to the Regional Coordinating Center. Laboratory confirmation of SARS-CoV-2 was defined as a positive result

### Key Points

**Question** What are the risk factors associated with mortality among critically ill patients with laboratory-confirmed coronavirus disease 2019 admitted to intensive care units in Lombardy, Italy?

**Findings** In this cohort study that involved 3988 critically ill patients admitted from February 20 to April 22, 2020, the hospital mortality rate as of May 30 was 12 per 1000 patient-days after a median observation time of 70 days. In the subgroup of the first 1715 patients, 865 (50.4%) had been discharged from the intensive care unit, 836 (48.7%) had died in the intensive care unit, and 14 (0.8%) were still in the intensive care unit; 915 patients died in the hospital for overall hospital mortality of (53.4%).

**Meaning** This study found that most critically ill patients with coronavirus disease 2019 in the intensive care unit required invasive mechanical ventilation, and mortality rate and absolute mortality rate were high.

of real-time reverse transcriptase-polymerase chain reaction assay of nasal and pharyngeal swabs and, in selected cases, confirmation with reverse transcriptase-polymerase chain reaction assay from lower respiratory tract aspirates.

The staff of the Regional Coordinating Center contacted each ICU of the Network daily by telephone and recorded on an electronic worksheet the demographic and clinical patient data. The following variables within the first 24 hours of ICU admission were recorded: age, sex, mode of respiratory support (IMV, noninvasive mechanical ventilation [NIV], oxygen mask), level of positive end-expiratory pressure (PEEP), fraction of inspired oxygen (FiO<sub>2</sub>), arterial partial pressure of oxygen (PaO<sub>2</sub>), PaO<sub>2</sub>:FiO<sub>2</sub> ratio, use of extracorporeal membrane oxygenation, and prone positioning. Preexisting comorbidities, long-term use of medications, and date of symptom onset were retrieved from the Regional Health System Database, which is based on the prescription of the general practitioners. The definitions of home intake of long-term medications and of each comorbidity, derived from the Regional Database, are presented in the eMethods in the Supplement.

The ICU and hospital outcomes of each patient were recorded on May 30, 2020. The interval from symptom onset to ICU admission, length of ICU stay, rate of reintubation, and rate of readmission to ICU were also evaluated.

### Statistical Analysis

Categorical variables are reported as frequencies (percentages with 95% CIs) and continuous variables as means (with SDs) or medians (with interquartile ranges [IQRs] and 95% CIs) according to distribution. Groups were compared with Wilcoxon rank sum tests with Benjamini and Hochberg correction for multiple comparison according to data distribution for continuous variables, and with Pearson  $\chi^2$  test (Fisher exact test where appropriate) for categorical variables.

Life status was determined for all patients as of May 30, 2020, from the Regional Health Authority. Time-to-event techniques were used to analyze survival from ICU admission. Overall mortality rate was calculated per 1000 patient-days. The ICU and hospital mortality rates were calculated

analogously, taking into account only time until ICU (or hospital) discharge.

Days from ICU admission to death (event) or May 30, 2020 (censoring), constituted the time of analysis. At the time of censoring, patients might be alive in the ICU, alive in hospital, or alive and discharged. For patients readmitted to the ICU after discharge, the first ICU admission was considered in the analysis.

We calculated Kaplan-Meier survival estimates and used the log-rank test to compare groups in terms of survival. The association of risk factors with time to death was assessed in univariable and multivariable Cox proportional hazards regression models. The proportional hazard assumption was tested by plotting the Nelson-Aalen cumulative hazard function and Schoenfeld residuals test.<sup>21</sup>

Four multivariable models were developed for demographics (model 1), comorbidities (model 2), drugs (model 3), and respiratory parameters (model 4) using variables strongly associated with mortality at univariable analysis, known from previous literature to be strongly associated with outcome and not collinear. We used the Akaike information criterion to compare different regression models and select the most parsimonious model.

The final model included independent factors from models 1 to 3 only (model 4 was run on a subset of data owing to missing data), with no further selection. The number of patients with missing data were 0 for outcomes, 82 for drugs, 688 for comorbidities, 1053 for PaO<sub>2</sub>, 984 for FiO<sub>2</sub>, 1074 for PaO<sub>2</sub>:FiO<sub>2</sub> ratio, and 958 for PEEP on ICU admission. Detailed information about missing data are reported in eFigure 1 in the Supplement.

A subgroup analysis was performed on the first 1715 patients, most of whom were included in a prior report.<sup>6</sup> As of May 30, 2020, 14 (0.8%) of these patients were still in the ICU, and 865 (50.4%) had been discharged from the ICU. A second subgroup analysis was performed on the 1643 patients with hypertension to explore the potential role of ACE inhibitors and antihypertensive drugs in this subset. A third subgroup analysis was performed on the 350 patients treated with NIV in the ICU to assess the association of NIV with patient outcomes. R software, version 4.0 (R CoreTeam, 2020), and STATA computer software, version 16.0 (StataCorp LLC), were used for data analysis. Two-sided *P* < .05 indicated significance.

## Results

### Description of the Cohort

From a population of 4209 patients admitted to ICUs in Lombardy with suspected SARS-CoV-2 infection to April 22, 2020, we excluded 127 patients with negative reverse transcriptase-polymerase chain reaction findings for SARS-CoV-2 and 94 patients missing results of reverse transcriptase-polymerase chain reaction for SARS-CoV-2. Data from 3988 patients (median age, 63 [IQR, 56-69] years) were analyzed. Table 1 shows the associations between demographic and baseline characteristics and mortality. Most patients were men (3188

[79.9%; 95% CI, 78.7%-81.1%]), with a median age of 63 (95% CI, 62-63; IQR, 55-69) years. Eight hundred patients were women (20.1%; 95% CI, 18.9%-21.3%), with a median age of 64 (95% CI, 63-65; IQR, 57-70) years. Median time from symptom onset to ICU admission was 10 (95% CI, 9-10; IQR, 6-14) days. One thousand nine hundred and ninety-eight of 3300 patients (60.5%; 95% CI, 58.9%-62.2%) had at least 1 comorbidity. Hypertension was the most common comorbidity (1643 [42.1%; 95% CI, 40.5%-43.6%]), followed by hypercholesterolemia (545 [16.5%; 95% CI, 15.3%-17.8%]) and heart disease (533 [16.2%; 95% CI, 14.9%-17.4%]).

### Observation Time and Main Outcomes

Cumulative observation time was 164 305 patient-days from ICU admission to end of follow-up for the 3988 patients (median observation time, 70 [range, 38-112] days; IQR, 61-70 days). After a median follow-up of 69 (IQR, 60-78; range, 38-100) days, there were 1926 deaths (overall mortality, 48.3%) for a mortality rate of 12 (95% CI, 11-12) per 1000 patient-days (Figure). There were 1769 ICU deaths (44.3%), for an ICU mortality rate of 27 (95% CI, 26-29) per 1000 patient-days. At the time of censoring, 91 patients (2.3%; 95% CI, 1.9%-2.8%) were still in the ICU, and 2049 (51.4%; 95% CI, 49.8%-52.9%) had been discharged from the ICU. Among the latter, 1480 patients (37.1%; 95% CI, 35.6%-38.6%) had been discharged from the hospital and 501 (12.6%; 95% CI, 11.6%-13.6%) were still hospitalized; the mortality rate after discharge from the ICU was 2 (95% CI, 1-2) per 1000 patient-days.

Distribution of patients' outcomes by ICU admission date is presented in the eFigure 2 in the Supplement. Median ICU stay was 12 (IQR, 6-21; range, 0-87) days, and the median duration of mechanical ventilation was 10 (IQR, 6-17; range, 0-87) days. Median length of stay in hospital was 28 (IQR, 15-48; range, 0-120) days.

Of the 2049 patients discharged from the ICU, 134 (6.5%) were readmitted to the ICU after discharge. Sixty-four of 3857 patients (1.7%) underwent extracorporeal membrane oxygenation support during the ICU stay, of whom 40 died (62.5%), 13 were discharged home (20.3%), and 11 were still hospitalized (17.2%).

At ICU admission, 2929 of 3355 patients (excluding 633 with missing data) underwent intubation (87.3%; 95% CI, 86.1%-88.4%). Three hundred and fifty patients underwent noninvasive respiratory support with NIV (10.4%; 95% CI, 9.4%-11.5%), which in most cases consisted of continuous positive air pressure delivered through a helmet or a standard oxygen mask (76 of 3355 patients [2.3%]).

### Univariable Analysis

A 10-year increase in age was significantly associated with mortality (hazard ratio [HR], 1.86; 95% CI, 1.76-1.96; *P* < .001). Patients 64 years or older had significantly decreased survival probability compared with younger patients (Figure).

Hypertension, hypercholesterolemia, heart disease, diabetes, malignant neoplasm, chronic obstructive pulmonary disease, chronic kidney disease, and all the studied medications taken at home before entering the hospital were associated with increased mortality at univariable analysis (Table 1

**Table 1. Demographic and Clinical Characteristics, Comorbidities, and Outcomes of 3988 Patients With COVID-19 Admitted to the ICU in Lombardy, Italy**

Characteristic <sup>a</sup>	No. of patients (n = 3988)	No. of deaths (n = 1926)	Mortality rate per 1000 patient-days	HR (95% CI)	P value
<b>Age, y</b>					
<56	997	245	4.5 (3.9-5.0)	1 [Reference]	NA
56-63	997	416	9.2 (8.3-10.1)	1.91 (1.63-2.24)	<.001
64-69	997	562	15.6 (14.3-16.9)	2.98 (2.56-3.46)	<.001
>69	997	703	25.2 (23.4-27.1)	4.25 (3.68-4.92)	<.001
<b>Sex</b>					
Men	3188	1580	12.2 (11.6-12.9)	1.22 (1.08-1.37)	<.001
Women	800	346	9.9 (8.8-10.9)	0.73 (0.82-0.92)	<.001
<b>Comorbidities</b>					
None	1302	490	7.7 (7.0-8.4)	0.55 (0.49-0.61)	<.001
Hypertension	1643	962	15.8 (14.8-16.8)	1.68 (1.53-1.84)	<.001
Hypercholesterolemia	545	376	22.4 (20.2-24.8)	1.90 (1.70-2.14)	<.001
Heart disease <sup>b</sup>	533	342	19.4 (17.4-21.5)	1.66 (1.48-1.87)	<.001
Type 2 diabetes	514	328	19.3 (17.3-21.5)	1.66 (1.47-1.88)	<.001
Malignant neoplasm <sup>c</sup>	331	202	17.3 (15.0-19.8)	1.45 (1.25-1.68)	<.001
COPD	93	67	25.4 (19.7-32.2)	2.03 (1.59-2.59)	<.001
CKD	87	71	39.3 (30.7-49.6)	2.78 (2.19-3.53)	<.001
Liver disease	86	42	11.4 (8.3-15.5)	1.03 (0.76-1.39)	.87
Other disease	501	274	13.7 (12.1-15.4)	1.19 (1.04-1.35)	.01
<b>Time from onset of symptoms to ICU admission, d</b>					
<6	922	510	14.4 (13.1-15.7)	1 [Reference]	NA
6-9	921	405	9.8 (8.8-10.8)	0.71 (0.62-0.81)	<.001
10-14	921	411	10.2 (9.3-11.3)	0.73 (0.64-0.83)	<.001
>14	921	455	13.1 (11.9-14.4)	0.84 (0.74-0.95)	.006
<b>Length of ICU stay, d</b>					
<6	994	615	22.8 (21.0-24.7)	1 [Reference]	NA
6-11	993	528	14.3 (13.1-15.6)	0.59 (0.52-0.66)	<.001
12-21	994	475	11.0 (10.1-12.1)	0.42 (0.38-0.48)	<.001
>21	993	308	5.5 (4.9-6.1)	0.23 (0.20-0.27)	<.001
<b>Length of IMV, d</b>					
<6	634	480	37.8 (34.5-41.3)	1 [Reference]	NA
6-9	634	413	21.8 (19.7-23.9)	0.52 (0.46-0.60)	<.001
10-17	634	384	16.7 (15.1-18.5)	0.32 (0.37-0.43)	<.001
>17	633	368	12.9 (11.6-14.3)	0.29 (0.25-0.41)	<.001
<b>Length of hospital stay, d</b>					
<15	925	837	77.7 (72.7-83.3)	1 [Reference]	NA
15-27	924	565	16.9 (15.5-18.4)	0.21 (0.19-0.24)	<.001
28-48	924	268	5.4 (4.7-5.9)	0.07(0.06-0.08)	<.001
>48	924	58	0.9 (0.7-1.2)	0.01 (0.01-0.02)	<.001
<b>Ventilation on ICU admission</b>					
Respiratory support	76	13	3.3 (1.7-5.6)	1	
NIV	350	127	7.4 (6.1-8.7)	2.36 (1.33-4.17)	.003
IMV	2929	1514	13.0 (12.4-13.7)	3.77 (2.19-6.51)	<.001
<b>Pao<sub>2</sub>, mm Hg</b>					
<76	734	404	14.9 (13.5-16.5)	1 [Reference]	NA
76-93	734	381	13.2 (11.9-14.6)	0.89 (0.77-1.02)	.10
94-127	734	341	10.7 (9.6-11.9)	0.74 (0.64-0.85)	<.001
>127	733	337	10.4 (9.3-11.6)	0.73 (0.63-0.84)	<.001

(continued)

**Table 1. Demographic and Clinical Characteristics, Comorbidities, and Outcomes of 3988 Patients With COVID-19 Admitted to the ICU in Lombardy, Italy (continued)**


Characteristic <sup>a</sup>	No. of patients (n = 3988)	No. of deaths (n = 1926)	Mortality rate per 1000 patient-days	HR (95% CI)	P value
<b>FiO<sub>2</sub>, %</b>					
<60	751	276	7.5 (6.6-8.4)	1 [Reference]	NA
60-69	751	373	11.6 (10.4-12.8)	1.46 (1.25-1.71)	<.001
70-85	751	344	10.9 (9.8-12.1)	1.35 (1.16-1.59)	<.001
>85	751	501	22.5 (20.6-24.6)	2.49 (2.15-2.89)	<.001
<b>PaO<sub>2</sub>:FiO<sub>2</sub> ratio</b>					
<103	729	461	20.2 (18.4-22.1)	1 [Reference]	NA
103-144	728	384	13.6 (12.2-14.9)	0.7 (0.61-0.80)	<.001
145-203	729	352	11.3 (10.1-12.6)	0.6 (0.53-0.69)	<.001
>203	728	259	7.1 (6.2-7.9)	0.41 (0.35-0.48)	<.001
<b>PEEP, cm H<sub>2</sub>O</b>					
<10	758	364	12.2 (10.9-13.5)	1 [Reference]	NA
10-12	757	343	10.6 (9.5-11.7)	0.92 (0.79-1.06)	.25
13-15	758	402	13.3 (12.1-14.7)	1.15 (1.0-1.33)	.049
>15	757	412	13.3 (12.2-14.6)	1.19 (1.03-1.37)	.02

Abbreviations: CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; FiO<sub>2</sub>, fraction of inspired oxygen; HR, hazard ratio; ICU, intensive care unit; IMV, invasive mechanical ventilation; NA, not applicable; NIV, noninvasive mechanical ventilation; PaO<sub>2</sub>, arterial partial pressure of oxygen; PEEP, positive end-expiratory pressure.

<sup>a</sup> Continuous variables were divided in quartiles and compared using the z test from the Cox proportional hazards regression models.

<sup>b</sup> Includes cardiomyopathy and heart failure.

<sup>c</sup> Includes active neoplasia and neoplasia in remission.

**Figure. Kaplan-Meier Analysis of Survival of Patients Admitted to the Intensive Care Unit**

Survival is reported for the overall group and stratified by median age (<64 or ≥64 years).

and eTable 2 in the Supplement). A 10% increase in FiO<sub>2</sub> on the first day of ICU admission was associated with increased mortality (HR, 1.24; 95% CI, 1.20-1.27; *P* < .001), whereas a 100-point increase in PaO<sub>2</sub>:FiO<sub>2</sub> ratio decreased by 44% the hazard for mortality (HR, 0.66; 95% CI, 0.61-0.71; *P* < .001).

### Multivariable Analysis

At multivariable analysis, a 10-year increase in age (HR, 1.75; 95% CI, 1.60-1.92) and male sex (HR, 1.57; 95% CI, 1.31-1.88) were significantly associated with mortality (Table 2 and eFigure 3 in the Supplement). Among comorbidities, history of chronic obstructive pulmonary disease (HR, 1.68; 95% CI, 1.28-2.19), hypercholesterolemia (HR, 1.25; 95% CI, 1.02-1.52), and diabetes (HR, 1.18; 95% CI, 1.01-1.39) were significantly associated with mortality. No long-term use of a medication was independently associated with mortality after controlling for other factors (ACE inhibitors HR, 1.17 [95% CI,

0.97-1.42]; angiotensin receptor blockers [ARBs] HR, 1.05 [95% CI, 0.85-1.29]). Decreased PEEP (HR, 1.04; 95% CI, 1.01-1.06) and FiO<sub>2</sub> (HR, 1.14; 95% CI, 1.10-1.19) and increased PaO<sub>2</sub>:FiO<sub>2</sub> ratio (HR, 0.80; 95% CI, 0.74-0.87) at ICU admission were independently associated with improved survival.

### Subgroup Analyses

In the subgroup analysis of the first 1715 patients (minimum follow-up of 73 days), the hospital mortality was 915 patients (53.4%; 95% CI, 50.9%-55.7%), with 836 (48.7%; 95% CI, 46.4%-51.1%) dying in the ICU and 79 (4.6%; 95% CI, 3.7%-5.7%) dying after ICU discharge. Table 3 shows the univariable associations of baseline characteristics and comorbidities in this subgroup. As of May 30, 2020, 14 patients (0.8%) were still in the ICU and 127 (7.4%) were still hospitalized; the median observation time was 80 (range, 76-112) days. The median ICU length of stay of patients who died in the ICU was



Table 2. Multivariable Cox Proportional Hazards Regression Analysis of Factors Associated With Mortality

Variable	Category (description)	Multivariable HR (95% CI)	P value <sup>a</sup>
Age in years	10-y Increments	1.75 (1.60-1.92)	<.001
Men	Men vs women	1.57 (1.31-1.88)	<.001
Respiratory support	Spontaneous breathing vs NIV	1.81 (0.57-5.76)	.32
	Invasive MV vs NIV	1.24 (1.00-1.55)	.052
Hypertension	Yes vs no	0.99 (0.81-1.22)	.93
Hypercholesterolemia	Yes vs no	1.25 (1.02-1.52)	.03
Heart disease	Yes vs no	1.08 (0.91-1.29)	.38
Type 2 diabetes	Yes vs no	1.18 (1.01-1.39)	.04
Malignancy	Yes vs no	1.09 (0.92-1.28)	.33
COPD	Yes vs no	1.68 (1.28-2.19)	<.001
ACE inhibitor therapy	Yes vs no	1.17 (0.97-1.42)	.10
ARB therapy	Yes vs no	1.05 (0.85-1.29)	.64
Statin	Yes vs no	0.98 (0.81-1.20)	.87
Diuretic	Yes vs no	1.10 (0.91-1.32)	.32
PEEP at admission	1-cm H <sub>2</sub> O increments	1.04 (1.01-1.06)	.009
Fio <sub>2</sub> at admission	10% Increments	1.14 (1.10-1.19)	<.001
Pao <sub>2</sub> /Fio <sub>2</sub> at admission	100-U increments	0.80 (0.74-0.87)	<.001

Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; COPD, chronic obstructive pulmonary disease; Fio<sub>2</sub>, fraction of inspired oxygen; HR, hazard ratio; IMV, Invasive mechanical ventilation; MV, mechanical ventilation; NIV, noninvasive mechanical ventilation; Pao<sub>2</sub>, arterial partial pressure of oxygen; PEEP, positive end-expiratory pressure.

<sup>a</sup> Calculated using the z test from Cox proportional hazards regression models.

10 (IQR, 5-16) days; for those discharged from the ICU, 15 (IQR, 8-24) days.

In the subgroup of 1643 patients with a history of hypertension, long-term home treatment with ACE inhibitors,  $\beta$ -blockers, statins, and diuretics was associated with higher mortality at univariable analysis (eTable 2 in the Supplement). The subgroup of 350 patients initially treated with NIV had lower levels of PEEP (eTable 1 in the Supplement) and a lower hazard for mortality (HR, 0.62; 95% CI, 0.52-0.75;  $P < .001$ ) than patients treated with IMV. The 151 patients initially treated noninvasively and subsequently undergoing intubation (after a median of 3 [IQR, 2-4; range, 0-15] days) had a significantly lower chance of survival compared with the 199 patients who continued to undergo NIV during the entire ICU stay (HR, 1.69; 95% CI, 1.43-1.98;  $P < .001$ ). The mortality of the patients undergoing subsequent intubation was similar to that for the patients who were treated with mechanical ventilation for ICU admission (HR for IMV vs NIV failure, 1.20; 95% CI, 0.95-1.53;  $P = .12$ ). eTable 1 and eFigure 4 in the Supplement show the overall survival data for patients in this subgroup.

## Discussion

In a cohort of 3988 critically ill patients with laboratory-confirmed SARS-CoV-2 infection admitted to an ICU during the first 2 months of the COVID-19 outbreak in Lombardy, Italy, the estimated ICU and hospital mortality rates were 27 and 12 per 1000 patient-days, respectively. In the subset of the first 1715 patients, ICU and hospital mortality were 48.8% and 53.4%, respectively. This mortality is almost double that described in the initial report,<sup>6</sup> in which the ICU mortality was 25.6% but 58.2% of the patients were still in the ICU at the end of follow-up. These sobering statistics highlight the long ICU

stays, prolonged need for respiratory support, and high mortality of COVID-19 in critically ill patients.

At the beginning of the COVID-19 outbreak in Lombardy, many patients required ICU admission in a limited period.<sup>2,22</sup> Hence, the ICU capacity had to be rapidly increased by establishing a network of COVID-19 ICUs in many hospitals. Experience in the treatment of patients with acute respiratory failure and the physician-to-patient and nurse-to-patient ratios varied widely among the centers, and this might have had an effect on patient outcomes.<sup>23,24</sup> Mortality of patients critically ill with COVID-19 varies significantly among the published case series, ranging from 16% to 78%.<sup>7,8,10-12,18-20</sup> This wide variability can be explained by different case mixes, different organization, availability of ICU beds among different countries, and different lengths of follow-up. In a case series of ICU patients in China, 28-day ICU mortality was 39% for the entire ICU population (344 patients) but reached 97% in the subgroup of 100 patients requiring IMV.<sup>9</sup> In the case series of critically ill patients from Washington State<sup>18</sup> and the Seattle region,<sup>12</sup> 71% and 75% of patients required IMV, respectively. Mortality calculated with a minimum follow-up of 12 days was 67% in Washington State; with a minimum follow-up of 14 days, 50%.

Importantly, patients included in our series were the sickest patients, those treated in high-intensity (level 3) areas, as demonstrated by the very high proportion of patients (87.3%) undergoing IMV at ICU admission. Many more patients in Italy, not described herein, have been treated in lower-intensity (level 2) areas, created ad hoc for the COVID-19 crisis, with extended monitoring and noninvasive respiratory support.

Our findings confirm that survival of critically ill patients with COVID-19 is particularly low for older men requiring IMV and with preexisting comorbidities. Hypertension was the most frequent comorbidity, and patients with hypertension had significantly decreased survival. Despite this, in the multivari-

Table 3. Demographic and Clinical Characteristics, Comorbidities, and Outcomes of the First 1715 Patients

Variable	Overall <sup>a</sup>	ICU			P value <sup>b</sup>	Hospital			P value <sup>b</sup>
		Death in ICU	Discharged from ICU	Still in ICU		Death in hospital	Discharged from hospital	Still in hospital	
All patients	1715 (100)	836 (48.7)	865 (50.4)	14 (0.8)	.50	915 (53.4)	673 (39.2)	127 (7.4)	.50
Men	1398/1715 (81.5)	700 (50.1)	688 (49.2)	10 (0.7)	.03	763 (54.6)	534 (38.2)	101 (7.2)	.046
Women	317/1715 (18.5)	136 (42.9)	177 (55.8)	4 (1.3)		152 (47.9)	139 (43.8)	26 (8.2)	
Age, median (IQR), y	64 (56-70)	68 (62-73)	59 (52-66)	62 (52-65)	<.001	68 (62-73)	58 (51-64)	62 (55-67)	<.001
Comorbidities	1078/1652 (65.3)	594 (55.1)	474 (44.0)	10 (0.9)	<.001	653 (60.6)	357 (33.1)	68 (6.3)	<.001
None	574/1652 (34.7)	211 (36.8)	359 (62.5)	4 (0.7)	<.001	228 (39.7)	292 (50.9)	54 (9.4)	<.001
Hypertension	890/1703 (52.3)	500 (56.2)	382 (42.9)	8 (0.9)	<.001	551 (61.9)	283 (31.8)	56 (6.3)	<.001
Hypercholesterolemia	302/1652 (18.3)	191 (63.2)	110 (36.4)	1 (0.3)	<.001	214 (70.9)	74 (24.5)	14 (4.6)	<.001
Heart disease <sup>c</sup>	318/1652 (19.2)	198 (62.3)	117 (36.8)	3 (0.9)	<.001	224 (70.4)	76 (23.9)	18 (5.7)	<.001
Diabetes	284/1652 (17.2)	182 (64.1)	100 (35.2)	2 (0.7)	<.001	201 (70.8)	66 (23.2)	17 (6.0)	<.001
Malignant neoplasm <sup>d</sup>	191/1652 (11.6)	113 (59.2)	78 (40.8)	0	.004	122 (63.9)	59 (30.9)	10 (5.2)	.005
COPD	58/1652 (3.5)	39 (67.2)	19 (32.8)	0	.007	45 (77.6)	11 (19.0)	2 (3.4)	<.001
CKD	52/1652 (3.1)	41 (78.8)	11 (21.2)	0	<.001	44 (84.6)	7 (13.5)	1 (1.9)	<.001
Liver disease	45/1652 (2.7)	19 (42.2)	26 (57.8)	0	.43	21 (46.7)	20 (44.4)	1 (2.2)	.79
Other disease	271/1652 (16.4)	141 (52.0)	128 (47.2)	2 (0.7)	.26	155 (57.2)	98 (36.2)	18 (6.6)	.21
Time from onset of symptoms to ICU admission, median (IQR), d	8 (4-11)	7 (4-10)	8 (5-11)	9 (4-11)	.14	7 (4-10)	8 (5-11)	8 (4-11)	.07
No. of patients	1588	769	807	12	NA	844	631	113	NA
Length of ICU stay, median (IQR), d	12 (7-20)	10 (5-16)	15 (8-24)	76 (74-80)	<.001	10 (5-16)	14 (8-22)	33 (18-54)	<.001
No. of patients	1711	836	861	14	NA	915	669	127	NA
Length of hospital stay, median (IQR), d	22 (12-42)	12 (8-19)	39 (24-61)	79 (74-84)	<.001	13 (8-20)	37 (23-53)	84 (79-88)	<.001
No. of patients	1618	766	838	14	NA	838	658	122	NA
Length of mechanical ventilation, median (IQR), d	10 (6-16)	9 (5-15)	12 (7-18)	74 (73-78)	<.001	9 (5-15)	11 (7-17)	20 (13-65)	<.001
No. of patients	1171	787	370	14	NA	812	297	62	NA

Abbreviations: CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; IQR, interquartile range; NA, not applicable.

<sup>a</sup> Unless otherwise indicated, data are expressed as number/total number (percentage) of patients for overall population and number (percentage) of row total for other columns.

<sup>b</sup> Calculated for death vs discharge using Wilcoxon rank sum tests or  $\chi^2$  test according to continuous or categorical variables.

<sup>c</sup> Includes cardiomyopathy and heart failure.

<sup>d</sup> Includes active neoplasia and neoplasia in remission.

able analysis, hypertension was not an independent factor associated with mortality. Conversely, a history of chronic obstructive pulmonary disease, hypercholesterolemia, and diabetes, although affecting a smaller percentage of patients, were independently associated with mortality.

The pathophysiology of acute respiratory failure in patients with COVID-19 is poorly understood. Some reports show a significant mismatch between the degree of hypoxemia and a relatively minor compromise of respiratory system compliance.<sup>25</sup> This mismatch may indicate that the optimal setting of mechanical ventilation in these patients may be different from that commonly applied in usual forms of acute respiratory distress syndrome. Levels of PEEP applied in our patients at ICU admission were higher than those reported for the management of moderate to severe acute respiratory distress syndrome in the pre-COVID-19 era.<sup>26</sup> High PEEP levels and  $\text{FiO}_2$  and low  $\text{PaO}_2$ : $\text{FiO}_2$  ratio at ICU admission were all independent factors associated with mortality.

Data on the effect of drugs acting on the renin-angiotensin system are of particular interest because ACE2 is the primary receptor for SARS-CoV-2 entry into the host cells.<sup>17</sup> Preclinical data support the hypothesis that long-term intake of ACE inhibitors, ARBs, statins, corticosteroids, and hypoglycemic agents may increase susceptibility to SARS-CoV-2 infection by favoring viral replication owing to upregulation of ACE2 receptors.<sup>27-31</sup> On the other hand, in patients with COVID-19, these same drugs may theoretically improve the clinical course by rebalancing the dysregulated renin-angiotensin system and thus reducing vasoconstriction, inflammation, and oxidation. In a recent large case series, mortality of patients with hypertension taking ACE inhibitors or ARBs was higher than that of patients with hypertension not taking these drugs, but no statistic confirmed the association between chronic therapy with ACE inhibitors or ARBs and mortality.<sup>10</sup> In our patients, long-term treatment with ACE inhibitors, ARBs,  $\beta$ -blockers, statins, diuretics, antiplatelet drugs, and anticoagulants before ICU admission was associated with higher

mortality in an unadjusted analysis only. This finding should be interpreted with caution, because unmeasured confounders could explain this observation, as demonstrated by the fact that the multivariable analysis did not confirm the association between any home therapies and increased mortality.

### Limitations

This study has several limitations. First, it is a retrospective study based on data mainly collected by telephone primarily for clinical purposes. We were able to cross-link demographic data from other health care databases; however, this was mainly a real-life database made for operational reasons. We could not assess the effect of other important variables, such as weight, body mass index, smoking history, and respiratory system compliance. Second, some variables have missing data (eFigure 1 in the Supplement), mainly owing to the reasons mentioned above. Third, preexisting comorbidities and chronic medications were retrieved from the regional health system database; therefore, the severity of the comorbidities and patient compliance with medical prescriptions could not be evaluated. Moreover, we do not have information on how many patients maintained their long-term medication regimens during the ICU stay, which may be relevant, particularly for drugs acting on the renin-angiotensin system.

In addition, another important limitation concerns some peculiar organizational aspects of intensive care services of the Italian health care system. During this crisis, we increased the total capacity of both our higher-intensity (level 3) and lower-intensity (level 2) areas to increase our potential for respiratory support. All patients with COVID-19 undergoing intubation were treated in level 3 areas and are described in this report, whereas most patients who did not undergo intubation were treated in level 2 areas. For these reasons, we believe that our data provide important insights about patients requiring IMV but should not be extrapolated to the population of patients requiring other forms of advanced noninvasive respiratory support.

### Conclusions

SARS-CoV-2 represents a massive challenge for health care systems and the ICUs in Italy and throughout the world.<sup>2</sup> A high volume of patients with the same disease required access to intensive treatments at the same time. Until effective and specific therapies are available, supportive care is the mainstay of treatment for critically ill patients.<sup>32,33</sup> Providing this care at a high-quality level for the high volume of patients to treat is a challenge for all health care systems.

#### ARTICLE INFORMATION

**Accepted for Publication:** June 18, 2020.

**Published Online:** July 15, 2020.

doi:10.1001/jamainternmed.2020.3539

**Author Affiliations:** Dipartimento di Anestesia, Rianimazione e Emergenza-Urgenza, Fondazione IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico) Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy (Grasselli, Zanella, Pesenti); Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy (Grasselli, Zanella, Carlesso, Pesenti); Department of Anesthesia and Intensive Care Medicine, Humanitas Clinical and Research Center-IRCCS, Rozzano, Italy (Greco, Cecconi); Department of Biomedical Sciences, Humanitas University, Milan, Italy (Greco, Cecconi); Humanitas Gavazzeni, Bergamo, Italy (Albano); Department of Anesthesiology, Intensive Care and Emergency Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy (Antonelli); Dipartimento di Scienze biotecnologiche di base, cliniche intensivologiche e perioperatorie, Università Cattolica del Sacro Cuore, Rome, Italy (Antonelli); Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy (Bellani, Foti, Fumagalli, Langer); Department of Anesthesia and Intensive Care Medicine, Azienda Socio Sanitaria Territoriale (ASST) Monza-Ospedale San Gerardo, Monza, Italy (Bellani, Foti); Department of Anesthesia and Intensive Care, ASST Papa Giovanni XXIII, Bergamo, Italy (Bonanomi, Lorini); Università degli Studi dell'Insubria, Azienda Ospedaliera Ospedale di Circolo e Fondazione Macchi, Varese, Italy (Cabrini); Department of Anesthesiology and Intensive Care, ASST Mantova-Ospedale Carlo Poma, Mantova, Italy (Castelli); Department of Anaesthesiology, Intensive Care and Perioperative Medicine, Spedali Civili University Hospital, Brescia, Italy (Cattaneo,

Latronico); Direzione Generale (DG) Welfare, Lombardy Region, Milan, Italy (Cereda, Tirani); Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy (Colombo); Department of Anesthesiology and Intensive Care, ASST Cremona-Ospedale di Cremona, Cremona, Italy (Coluccello, Crescini); Department of Anesthesiology and Intensive Care, ASST Lecco-Ospedale di Lecco, Lecco, Italy (Forastieri Molinari); Dipartimento di Anestesia e Rianimazione, Grande Ospedale Metropolitano Niguarda, Milan, Italy (Fumagalli, Langer); Department of Intensive Medicine, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy (Iotti, Mojoli); Department of Clinical-Diagnostic, Surgical and Pediatric Sciences, University of Pavia, Pavia, Italy (Iotti, Mojoli); Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy (Latronico); Department of Anesthesia and Intensive Care, Fondazione Poliambulanza Hospital, Brescia, Italy (Natalini, Rosano); Department of Anesthesia and Intensive Care, ASST Rhodense-Presidio di Rho, Milano, Italy (Pessina); Anesthesia and Intensive Care Medicine, Policlinico di Sant'Orsola, Alma Mater Studiorum University of Bologna, Bologna, Italy (Ranieri); Department of Anesthesiology and Intensive Care, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Polo Universitario, University of Milan, Milan, Italy (Rech); Direzione Scientifica, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy (Scudeller); Dipartimento Emergenza Urgenza, Unità Operativa Complessa (UOC) Anestesia e Rianimazione, ASST, Lodi, Italy (Storti, Villani); Division of Pulmonary and Critical Medicine, Massachusetts General Hospital, Boston (Thompson); Health Protection Agency of Pavia, Pavia, Italy (Tirani).

**Author Contributions:** Drs Grasselli and Greco contributed equally as co-first authors. Drs Pesenti

and Cecconi contributed equally as co-last authors. Drs Greco and Zanella had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

**Concept and design:** Grasselli, Greco, Zanella, Antonelli, Cabrini, Langer, Ranieri, Scudeller, Pesenti, Cecconi.

**Acquisition, analysis, or interpretation of data:** All authors.

**Drafting of the manuscript:** Grasselli, Greco, Zanella, Albano, Bonanomi, Cereda, Colombo, Crescini, Forastieri Molinari, Pessina, Rech, Pesenti, Cecconi.

**Critical revision of the manuscript for important intellectual content:** Grasselli, Zanella, Antonelli, Bellani, Cabrini, Carlesso, Castelli, Cattaneo, Coluccello, Foti, Fumagalli, Iotti, Langer, Latronico, Lorini, Mojoli, Natalini, Ranieri, Scudeller, Rosano, Storti, Thompson, Tirani, Villani, Pesenti, Cecconi.

**Statistical analysis:** Greco, Zanella, Coluccello, Latronico, Scudeller, Cecconi.

**Administrative, technical, or material support:** Grasselli, Bellani, Carlesso, Cattaneo, Forastieri Molinari, Langer, Latronico, Lorini, Rosano.

**Supervision:** Grasselli, Zanella, Albano, Antonelli, Bonanomi, Foti, Fumagalli, Iotti, Langer, Latronico, Lorini, Mojoli, Ranieri, Storti, Pesenti, Cecconi.

**Conflict of Interest Disclosures:** Dr Grasselli reported receiving personal fees from Getinge Group, Biotest, Draeger Medical Systems, Inc, Thermo Fisher Scientific, and Fisher & Paykel outside the submitted work. Dr Zanella reported holding patents to WO2016189427 and WO20151855837 (licensed). Dr Bellani reported receiving grants and personal fees from Draeger Medical Systems, Inc, and Dimar SRL and personal fees from Hamilton Medical Products, Inc, Getinge Group, GE Healthcare, and Intersurgical outside the submitted work. Dr Iotti reported receiving personal fees from Hamilton Medical Products, Inc, Intersurgical, Maquet Italia, Cinisello Balsamo Eurosets, and Burke & Burke outside the submitted



work. Dr Mojoli reported receiving fees for lectures from Hamilton Medical Products, Inc, GE Healthcare, and Seda SpA and a consultancy agreement between University of Pavia and Hamilton Medical Products, Inc. Dr Thompson reported receiving personal fees from Bayer AG outside the submitted work. Dr Pesenti reported receiving personal fees from Maquet Italia, Novalung/Xenios AG, Baxter International, Inc, and Boehringer Ingelheim outside the submitted work. Dr Ceconi reported receiving personal fees from Edwards Lifesciences, Directed Systems, and Cheetah Medical, Inc, outside the submitted work. No other disclosures were reported.

**Group Information:** The COVID-19 Lombardy ICU Network includes the following participants: Emiliano Agosteo, MD, Clinica "San Carlo" Paderno Dugnano, Milan, Italy; Giovanni Albano, MD, Humanitas Gavazzeni, Bergamo, Italy; Andrea Albertin, MD, Department of Anaesthesia and Intensive Care, San Giuseppe Hospital, Multimedita Group, Milan, Italy; Armando Alborghetti, MD, Department of Anaesthesia and Intensive Care, Policlinico San Pietro-Ponte San Pietro, Italy; Giorgio Aldegheri, MD, Department of Anaesthesiology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Multimedica, Sesto San Giovanni, Milano, Italy; Benvenuto Antonini, MD, Department of Anaesthesia and Intensive Care, Azienda Socio Sanitaria Territoriale (ASST) Garda-Ospedale di Manerbio, Manerbio, Italy; Enrico Barbara, MD, Department of Anaesthesia and Intensive Care, Humanitas Mater Domini Hospital, Castellanza, Varese, Italy; Giulia Bardelloni, MD, Department of Medicine and Surgery, University of Milano-Bicocca, and Department of Anesthesia and Intensive Care Medicine, ASST Monza-Ospedale San Gerardo, Monza, Italy; Sabrina Basilico, MD, Department of Anesthesia and Intensive Care Unit, ASST Lariana, Como, Italy; Nicolangela Belgiorio, MD, Department of Anaesthesia and Intensive Care, Istituto Clinico San Rocco, Ome, Italy; Giacomo Bellani, MD, Department of Medicine and Surgery, University of Milano-Bicocca, and Department of Anesthesia and Intensive Care Medicine, ASST Monza-Ospedale San Gerardo, Monza, Italy; Enrico Beretta, MD, Unit of Anesthesia and Intensive Care, ASST Valtellina e Alto Lario, Ospedale E. Morelli, Sondalo, Italy; Angela Berselli, MD, Department of Anesthesiology and Intensive Care, ASST Mantova-Ospedale Carlo Poma, Mantova, Italy; Leonardo Bianciardi, MD, Department of Anaesthesia and Intensive Care, Hospital of Pieve di Coriano, ASST Mantova, Mantova, Italy; Ezio Bonanomi, MD, Department of Anaesthesia and Intensive Care, ASST Papa Giovanni XXIII, Bergamo, Italy; Stefano Bonazzi, MD, Department of Anaesthesia and Intensive Care, Hospital MOA Locatelli, Piario, ASST Bergamo Est, Bergamo, Italy; Massimo Borelli, MD, Department of Anaesthesia and Intensive Care, Ospedale Treviglio-Caravaggio, Treviglio, Italy; Nicola Bottino, MD, Dipartimento di Anestesia, Rianimazione e Emergenza-Urgenza, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Nicola Bronzini, MD, Department of Anaesthesia and Intensive Care, Clinical Institute Sant'Anna, Brescia, Italy; Serena Brusatori, MD, Regional Coordinating Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, and University of Milan, Milan, Italy; Luca Cabrini, MD, Università degli Studi dell'Insubria and Azienda Ospedaliera Ospedale di Circolo e Fondazione

of Biotechnology and Sciences of Life, ASST-Setteleghi Ospedale di circolo e Fondazione Macchi, University of Insubria, Varese, Italy; Livio Carnevale, MD, Department of Anaesthesia and Intensive Care, ASST Pavia-Ospedale di Vigevano, Vigevano, Italy; Gianpaolo Castelli, MD, Department of Anesthesiology and Intensive Care, ASST Mantova-Ospedale Carlo Poma, Mantova, Italy; Emanuele Catena, MD, Department of Anesthesia and Intensive Care Unit, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Polo Universitario, University of Milan, Milan, Italy; Sergio Cattaneo, MD, Department of Anaesthesiology, Intensive Care and Perioperative Medicine, Spedali Civili University Hospital, Brescia, Italy; Maurizio Ceconi, MD, Department of Pathophysiology and Transplantation, University of Milan, and Department of Anaesthesia and Intensive Care Medicine, Humanitas Clinical and Research Center-IRCCS, Rozzano, Milan, Italy; Simona Celotti, MD, Humanitas Gavazzeni, Bergamo, Italy; Stefania Cerutti, MD, Department of Anaesthesia and Intensive Care, ASST Papa Giovanni XXIII, Bergamo, Italy; Davide Chiumello, MD, SC Anestesia e Rianimazione, Ospedale San Paolo-Polo Universitario, ASST Santi Paolo e Carlo, and University of Milan, Milan, Italy; Silvia Cirri, MD, Department of Anaesthesia and Intensive Care, Istituto Clinico Sant'Ambrogio, Milan, Italy; Giuseppe Citerio, MD, Department of Anaesthesia and Intensive Care, Hospital of Desio, ASST Monza, and Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy; Sergio Colombo, MD, Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy; Antonio Coluccello, MD, Department of Anesthesiology and Intensive Care, ASST Cremona-Ospedale di Cremona, Cremona, Italy; Davide Coppini, MD, Department of Anaesthesia and Intensive Care, ASST Garda-Ospedale Civile di La Memoria, Gavardo, Italy; Alberto Corona, MD, Department of Anaesthesia and Intensive Care, Ospedale di Valle Camonica Esine, ASST Vallecaminica, Brescia, Italy; Paolo Cortellazzi, MD, Department of Anaesthesia and Intensive Care, Ospedale Città di Sesto San Giovanni, ASST Nord Milano, Milan, Italy; Elena Costantini, MD, Department of Anaesthesia and Intensive Care Medicine, Humanitas Clinical and Research Center-IRCCS, Rozzano, Milan, Italy; Remo Daniel Covello, MD, Anesthesia and Intensive Care Unit, Busto Arsizio Hospital, ASST Valle Olona, Varese, Italy; Giuseppe Crescini, MD, Department of Anesthesiology and Intensive Care, ASST Cremona-Ospedale di Cremona, Cremona, Italy; Gianluca De Filippi, MD, Department of Anesthesia and Intensive Care, ASST Rhodense-Presidio di Rho, Milano, Italy; Marco Dei Poli, MD, Department of General Anesthesia and Intensive Care, IRCCS Policlinico San Donato, Milan, Italy; Paolo Dughi, MD, ASST Franciacorta, Ospedale di Iseo, Iseo, Italy; Fulvia Fieni, MD, Department of Anaesthesia and Intensive Care, Istituto Clinico San Rocco, Ome, Italy; Gaetano Florio, MD, Regional Coordinating Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, and University of Milan, Milan, Italy; Andrea Forastieri Molinari, MD, Department of Anesthesiology and Intensive Care, ASST Lecco, Ospedale di Lecco, Lecco, Italy; Giuseppe Foti, MD, Department of Medicine and Surgery, University of Milano-Bicocca, and Department of Anesthesia and Intensive Care Medicine, ASST Monza-Ospedale San Gerardo, Monza, Italy; Roberto Fumagalli, MD,

Department of Medicine and Surgery, University of Milano-Bicocca, and Dipartimento di Anestesia e Rianimazione Grande Ospedale Metropolitano Niguarda, Milan, Italy; Marco Galletti, MD, Department of Anaesthesia and Intensive Care, Ospedale Valduce, Como, Italy; Giorgio Antonio Galloli, MD, Department of Anaesthesia and Intensive Care, ASST Vimercate-Ospedale di Vimercate, Vimercate, Italy; Hedwige Gay, MD, Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy, and Dipartimento di Anestesia e Rianimazione Grande Ospedale Metropolitano Niguarda, Milan, Italy; Marco Gemma, MD, Department of Anaesthesia and Intensive Care, Fatebenefratelli Hospital, ASST Fatebenefratelli Sacco, Milan, Italy; Paolo Gnesin, MD, Department of Anesthesia and Intensive Care, ASST Franciacorta, Chiari, Brescia, Italy; Giacomo Grasselli, MD, Dipartimento di Anestesia, Rianimazione e Emergenza-Urgenza, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, and Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; Stefano Greco, MD, Department of Anaesthesia and Intensive Care, ASST Valle Olona-Ospedale di Saronno, Saronno, Italy; Massimiliano Greco, MD, Department of Pathophysiology and Transplantation, University of Milan, and Department of Anaesthesia and Intensive Care Medicine, Humanitas Clinical and Research Center-IRCCS, Rozzano, Milan, Italy; Paolo Grosso, MD, Department of Anaesthesia and Intensive Care, Policlinico di Monza, Monza, Italy; Luca Guatteri, MD, Department of Anaesthesia and Intensive Care, Ospedale Sacra Famiglia Fatebenefratelli, Erba, Italy; Davide Guzzon, MD, Department of Anaesthesia and Intensive Care, ASST Lecco-Ospedale di Merate, Merate, Italy; Giorgio Antonio Iotti, MD, Department of Intensive Medicine, Fondazione IRCCS Policlinico San Matteo, and Department of Clinical-Diagnostic, Surgical and Pediatric Sciences, University of Pavia, Pavia, Italy; Roberto Keim, MD, ASST Bergamo Est, Seriate, Italy; Thomas Langer, MD, Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy, and Dipartimento di Anestesia e Rianimazione Grande Ospedale Metropolitano Niguarda, Milan, Italy; Nicola Latronico, MD, Department of Anaesthesiology, Intensive Care and Perioperative Medicine, Spedali Civili University Hospital, and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy; Andrea Lombardo, MD, Department of Anesthesia and Intensive Care Unit, ASST Lariana, Como, Italy; Ferdinando Luca Lorini, MD, Department of Anaesthesia and Intensive Care, ASST Papa Giovanni XXIII, Bergamo, Italy; Filippo Mamprin, MD, ASST Bergamo Est, Seriate, Italy; Giovanni Marino, MD, Department of Anaesthesia and Intensive Care, ASST Melegnano-Ospedale di Vizzolo Predabissi, Melegnano, Italy; Francesco Marino, MD, Department of Anaesthesia and Intensive Care, Clinical Institute Betato Matteo, Vigevano, Pavia, Italy; Guido Merli, MD, Department of Anesthesia and Intensive Care Unit, Maggiore Hospital, Crema, Italy; Antonio Micucci, MD, Department of Anaesthesia and Intensive Care, Hospital Sant'Antonio Abate di Cantù, ASST Lariana, Como, Italy; Carmine Rocco Militano, MD, Department of Anesthesia and Intensive Care, Fondazione Poliambulanza Hospital, Brescia, Italy; Francesco Mojoli, MD, Department of Intensive Medicine, Fondazione IRCCS Policlinico San Matteo,

and Department of Clinical-Diagnostic, Surgical and Pediatric Sciences, University of Pavia, Pavia, Italy; Giacomo Monti, MD, Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy; Stefano Muttini, MD, Department of Anaesthesia and Intensive Care, ASST Santi Paolo e Carlo-Ospedale San Carlo, Milan, Italy; Samantha Nadalin, MD, Humanitas Gavazzeni, Bergamo, Italy; Giuseppe Natalini, MD, Department of Anesthesia and Intensive Care, Fondazione Poliambulanza Hospital, Brescia, Italy; Paolo Perazzo, MD, Department of Anaesthesia and Intensive Care, IRCCS Orthopedic Institute Galeazzi, Scientific Direction, Milan, Italy; Giovanni Battista Perego, MD, Department of Anaesthesia and Intensive Care, Istituto Auxologico San Luca, Milan, Italy; Luciano Perotti, MD, Department of Intensive Medicine, Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia, Italy; Antonio Pesenti, MD, Dipartimento di Anestesia, Rianimazione e Emergenza-Urgenza, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, and Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; Carla Maria Pessina, MD, Department of Anesthesia and Intensive Care, ASST Rhodense-Presidio di Rho, Milano, Italy; Nicola Petrucci, MD, Department of Anaesthesia and Intensive Care, ASST Garda-Ospedale di Desenzano D/G, Desenzano del Garda, Italy; Angelo Pezzi, MD, Department of Anaesthesia and Intensive Care, ASST Nord Milano-Ospedale Edoardo Bassini, Cinisello Balsamo, Italy; Simone Piva, MD, Department of Anaesthesiology, Intensive Care and Perioperative Medicine, Spedali Civili University Hospital, Brescia, Italy; Gina Portella, MD, Emergency-NGO, Milan, Italy; Alessandro Protti, MD, Department of Pathophysiology and Transplantation, University of Milan, Department of Anaesthesia and Intensive Care Medicine, Humanitas Clinical and Research Center-IRCCS, Rozzano, Milan, Italy; Milena Racagni, MD, Department of Anaesthesia and Intensive Care, ASST Santi Paolo e Carlo-Ospedale San Carlo, Milan, Italy; Danilo Radrizzani, MD, ASST Ovest Milanese-Ospedale Nuovo di Legnano Hospital, Legnano, Italy; Maurizio Raimondi, MD, Unità Operativa Complessa (UOC) Anestesia e Rianimazione, Ospedale Civile di Voghera ASST provincia di Pavia, Italy; Marco Ranucci, MD, Department of Cardiovascular Anaesthesia and Intensive Care Unit, IRCCS Policlinico San Donato, Milan, Italy; Roberto Rech, MD, Department of Anesthesia and Intensive Care Unit, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Polo Universitario, University of Milan, Milan, Italy; Mario Riccio, MD, Department of Anaesthesia and Intensive Care, Istituti Ospitalieri di Cremona-C.no Ospedale Oglio Po, Casalmaggiore, Italy; Antonio Rosano, MD, Department of Anesthesia and Intensive Care, Fondazione Poliambulanza Hospital, Brescia, Italy; Patrizia Ruggeri, MD, Department of Anesthesiology and Intensive Care, ASST Cremona-Ospedale di Cremona, Cremona, Italy; Giuseppe Sala, MD, Department of Anaesthesia and Intensive Care, Istituto Clinico Città Studi, Milan, Italy; Luca Salvi, MD, Department of Anaesthesia and Intensive Care, Centro Cardiologico Monzino, Milan, Italy; Pietro Sebastiano, MD, Department of Anaesthesia and Intensive Care, Istituto Clinico Città di Brescia-Istituti Ospedalieri Bresciani, Gruppo San Donato, Brescia, Italy; Paolo Severgnini, MD, Department of Biotechnology and Sciences of Life, ASST-Setteleghi Ospedale di circolo e Fondazione

Macchi, University of Insubria, Varese, Italy; Donato Sigurtà, MD, Department of Anaesthesia and Intensive Care, Istituto di Cura Città di Pavia, Pavia, Italy; Nino Stocchetti, MD, Dipartimento di Anestesia, Rianimazione e Emergenza-Urgenza, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, and Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; Enrico Storti, MD, Dipartimento Emergenza Urgenza, UOC Anestesia e Rianimazione, ASST, Lodi, Italy; Matteo Subert, MD, Department of Anaesthesia and Intensive Care, Hospital of Melzo, ASST Melegnano Martesana, Milan, Italy; Mario Tavola, MD, Department of Anesthesiology and Intensive Care, ASST Lecco, Ospedale di Lecco, Lecco, Italy; Serena Todaro, MS, Regional Coordinating Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, and University of Milan, Milan, Italy; Francesca Torriglia, MD, UOC Anestesia e Rianimazione, Ospedale Civile di Voghera ASST provincia di Pavia, Italy; Daniela Tubiolo, MD, Dipartimento di Anestesia, Rianimazione e Emergenza-Urgenza, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Roberto Valsecchi, MD, Department of Anaesthesia and Intensive Care, General Hospital Moriggia Pelascini Gravedona, Como, Italy; Pier Giorgio Villani, MD, Dipartimento Emergenza Urgenza, UOC Anestesia e Rianimazione, ASST, Lodi, Italy; Uberto Viola, MD, Department of Anaesthesia and Intensive Care, Ospedale San Pellegrino, Gruppo Mantova Salus, Mantova, Italy; Giovanni Vitale, MD, Department of Anaesthesia and Intensive Care, Policlinico San Marco, Zingonia, Italy; Massimo Zambon, MD, Department of Anaesthesia and Intensive Care, ASST Melegnano-Martesana, Presidio di Cernusco sul Naviglio, Italy; Alberto Zanella, MD, Dipartimento di Anestesia, Rianimazione e Emergenza-Urgenza, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, and Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; and Elena Zoia, MD, Department of Anaesthesia and Intensive Care, Children's Hospital Vittore Buzzi, ASST FBF Sacco, Milan, Italy.

**Funding/Support:** This study was supported in part by institutional funding (Ricerca corrente 2020) from the Department of Anesthesia, Critical Care and Emergency, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico.

**Role of the Funder/Sponsor:** The sponsor had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Additional Contributions:** Paolo Cadringer, MSc, Ospedale Maggiore Policlinico, provided support in data management. Chiara Paleari, MD, and Emanuele Cattaneo, MD, University of Milan, helped analyze the scientific literature. Marina Leonardelli and Patrizia Minunno, Ospedale Maggiore Policlinico, provided administrative support. We thank all the staff of the COVID-19 Lombardy ICU Network coordination: Caterina Accardo, MD, University of Milan; Alessio Altomare, MD, University of Milan; Chiara Anzanello, MD, University of Milan; Barbara Antonelli, MD, Ospedale Maggiore Policlinico; Andrea Arcari, MS, University of Brescia; Martina Barbieri, MS, University of Parma; Michele Battistin, MSc, Ospedale Maggiore Policlinico; Matteo Bertocchi, MS, University of Brescia; Lucio

Caccamo, MD, Ospedale Maggiore Policlinico; Elena Cadone Ughi, MD, University of Milan; Davide Calabretta, MD, University of Milan; Lorenzo Chiaravalli, MD; Daniela Codazzi, MD, DG Welfare Regione Lombardia; Sebastiano Colombo, MD, Ospedale Maggiore Policlinico; Bianca Della Santa, MD, University of Milan; Marianna Di Felicianantonio, MD, University of Milan; Daniele Dondossola, MD, Ospedale Maggiore Policlinico; Giulia Susanna Ferrero, MS, University of Milan; Chiara Fiorentini, MS, University of Milan; Chiara Galimberti, MS, University of Milan; Giorgio Giudici, MD, University of Milan; Giacomo Grisorio, MS, University of Milan; Amedeo Guzzardella, MD, University of Milan; Alessia Kersik, MD, University of Milan; Giacomo Mandarano, MS, University of Milan; Piergiorgio Mandarano, MS, University of Parma; Pier Luca Marazzi, MD, Fondazione Don Carlo Gnocchi; Barbara Marcora, MD, retired; Alessandra Mattioli, MS, University of Milan; Francesca Migliavacca, MD, University of Milan; Chiara Minaudo, MD, University of Milan; Matilde Moro, University of Parma; Luisa Napolitano, MD, Ospedale Maggiore Policlinico; Carolina Negro, MD, University of Milan; Elisa Paoluzzi Tomada, MD, University of Milan; Carolina Perali, MD, University of Milan; Arianna Pieroni, MD, University of Milan; Stefano Poggio, MD, University of Milan; Costanza Pucci, MD, University of Milan; Martina Ratti, MD, University of Milan; Serena Reato, MS, University of Milan; Anna Ribboni, MD, retired; Francesca Rossi, MD, Ospedale Maggiore Policlinico; Daniel Salvetti, MS, University of Parma; Simone Scarpino, MD, University of Milan; Francesco Scarri, MS, University of Milan; Ivan Silvestri, MS, University of Milan; Andrea Sozzi, MS, University of Milan; Camilla Storaci, MS, University of Milan; Lorenzo Tagliaferri, MS, University of Milan; Francesca Terenzi, MD, University of Milan; Martina Uzzo, MS, University of Milan; Clarissa Uslenghi, MS, University of Milan; Valentina Vago, MS, University of Milan; Oliviero Valori, MD, Ospedale Papa Giovanni XXIII; Carlo Valsecchi, MD, Ospedale Maggiore Policlinico; Chiara Vetrano, MS, University of Brescia; Luigi Vivona, MD, University of Milan; and Arianna Zefilippo, MD, Ospedale Maggiore Policlinico. Claudia Ebn, MD, Humanitas University, Pieve Emanuele, Italy, provided a critical review of English. Romina Aceto, MSc, Arianna De Buglio, MS, and Veronica Granone, MS, Humanitas University, Pieve Emanuele, Italy, provided support for data collection. Roberto Cefalà, MD, ASST Ovest Milanese, provided support to the ICU Network. Marco Salmoiraghi, MD, and Aida Andreassi, MD, DG Welfare Regione Lombardia, and all the staff of DG Welfare Regione Lombardia provided logistical and organizational support. We thank all the health care staff of the COVID-19 Lombardy ICU Network. These individuals were not compensated for their role in the study.

## REFERENCES

1. Covid-19 coronavirus pandemic. Updated July 3, 2020. Accessed April 12, 2020. <https://www.worldometers.info/coronavirus>
2. Grasselli G, Pesenti A, Cecconi M. Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response. *JAMA*. Published online March 13, 2020. doi:10.1001/jama.2020.4031
3. Lombardia Notizie Online. Posted November 7, 2019. Accessed April 12, 2020. <https://www.lombardianotizie.it>

regione.lombardia.it/wps/portal/istituzionale/HP/lombardia-notizie

4. Du RH, Liu LM, Yin W, et al. Hospitalization and critical care of 109 decedents with COVID-19 pneumonia in Wuhan, China. *Ann Am Thorac Soc*. 2020. doi:10.1513/AnnalsATS.202003-225OC
5. Grasselli G, Zangrillo A, Zanella A, et al; COVID-19 Lombardy ICU Network. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. *JAMA*. 2020;323(16):1574-1581. doi:10.1001/jama.2020.5394
6. Guan WJ, Ni ZY, Hu Y, et al; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med*. 2020;382(18):1708-1720. doi:10.1056/NEJMoa2002032
7. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395(10223):497-506. doi:10.1016/S0140-6736(20)30183-5
8. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA*. 2020. doi:10.1001/jama.2020.1585
9. Wang Y, Lu X, Li Y, et al. Clinical course and outcomes of 344 intensive care patients with COVID-19. *Am J Respir Crit Care Med*. 2020;201(11):1430-1434. doi:10.1164/rccm.202003-0736LE
10. Richardson S, Hirsch JS, Narasimhan M, et al; and the Northwell COVID-19 Research Consortium. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. *JAMA*. 2020;323(20):2052-2059. doi:10.1001/jama.2020.6775
11. Myers LC, Parodi SM, Escobar GJ, Liu VX. Characteristics of hospitalized adults with COVID-19 in an integrated health care system in California. *JAMA*. 2020;323(21):2195-2198. doi:10.1001/jama.2020.7202
12. Bhatraju PK, Ghassemieh BJ, Nichols M, et al. COVID-19 in critically ill patients in the Seattle region—case series. *N Engl J Med*. 2020;382(21):2012-2022. doi:10.1056/NEJMoa2004500
13. Anguiano L, Riera M, Pascual J, Soler MJ. Circulating ACE2 in cardiovascular and kidney diseases. *Curr Med Chem*. 2017;24(30):3231-3241. doi:10.2174/0929867324666170414162841
14. Diaz JH. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. *J Travel Med*. 2020;27(3):taaa041. doi:10.1093/jtm/taaa041
15. Ortiz-Pérez JT, Riera M, Bosch X, et al. Role of circulating angiotensin converting enzyme 2 in left ventricular remodeling following myocardial infarction: a prospective controlled study. *PLoS One*. 2013;8(4):e61695. doi:10.1371/journal.pone.0061695
16. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. *Nat Rev Cardiol*. 2020;17(5):259-260. doi:10.1038/s41569-020-0360-5
17. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell*. 2020;181(2):271-280.e8. doi:10.1016/j.cell.2020.02.052
18. Arentz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. *JAMA*. 2020;323(16):1612-1614. doi:10.1001/jama.2020.4326
19. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med*. 2020;8(5):475-481. doi:10.1016/S2213-2600(20)30079-5
20. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3
21. Kalbfleisch JD, Prentice RL. *The Statistical Analysis of Failure Time Data*. 2nd ed. Wiley; 2002. doi:10.1002/9781118032985
22. Carenzo L, Costantini E, Greco M, et al. Hospital surge capacity in a tertiary emergency referral centre during the COVID-19 outbreak in Italy. *Anaesthesia*. 2020;75(7):928-934. doi:10.1111/anae.15072
23. Azoulay E, Pochard F, Chevret S, et al; PROTOCETIC Group. Compliance with triage to intensive care recommendations. *Crit Care Med*. 2001;29(11):2132-2136. doi:10.1097/00003246-200111000-00014
24. Robert R, Reignier J, Tournoux-Facon C, et al; Association des Réanimateurs du Centre Ouest Group. Refusal of intensive care unit admission due to a full unit: impact on mortality. *Am J Respir Crit Care Med*. 2012;185(10):1081-1087. doi:10.1164/rccm.201104-0729OC
25. Marini JJ, Gattinoni L. Management of COVID-19 respiratory distress. *JAMA*. Published online April 24, 2020. doi:10.1001/jama.2020.6825
26. Bellani G, Laffey JG, Pham T, et al; LUNG SAFE Investigators; ESICM Trials Group. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. *JAMA*. 2016;315(8):788-800. doi:10.1001/jama.2016.0291
27. Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. *Circulation*. 2005;111(20):2605-2610. doi:10.1161/CIRCULATIONAHA.104.510461
28. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. *Hypertension*. 2004;43(5):970-976. doi:10.1161/01.HYP.0000124667.34652.1a
29. Jiang F, Yang J, Zhang Y, et al. Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets. *Nat Rev Cardiol*. 2014;11(7):413-426. doi:10.1038/nrcardio.2014.59
30. Karram T, Abbasi A, Keidar S, et al. Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure. *Am J Physiol Heart Circ Physiol*. 2005;289(4):H1351-H1358. doi:10.1152/ajpheart.01186.2004
31. Sánchez-Aguilar M, Ibarra-Lara L, Del Valle-Mondragón L, et al. Rosiglitazone, a ligand to PPAR $\gamma$ , improves blood pressure and vascular function through renin-angiotensin system regulation. *PPAR Res*. 2019;2019:1371758. doi:10.1155/2019/1371758
32. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. *JAMA*. 2020. doi:10.1001/jama.2020.6019
33. Alhazzani W, Møller MH, Arabi YM, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). *Intensive Care Med*. 2020;46(5):854-887. doi:10.1007/s00134-020-06022-5